The week in pharma: action, reaction and insight – week to July 5, 2024

By Barbara Obstoj-Cardwell. Editor

Research news was prominent last week, first with US healthcare giant Johnson & Johnson presenting new data on nipocalimab in the treatment of generalized myasthenia gravis (MS), pitching it against argenx’ Fc Rn blocker Vyvgart. Cartesian Therapeutics also reported positive top-line results for Descartes-08 in patients with myasthenia gravis, as well as a $130 financing. However, Roche released disappointing Phase II/III clinical trial results for its tiragolumab in combination with Tecentriq for non-small cell lung cancer (NSCLC), leading the Swiss pharma giant to halt the study. On the regulatory front, Eli Lilly gained long-awaited approval from the US Food and Drug Administration for its Alzheimer’s disease drug donanemab, to be marketed by the US pharma major under the trade name Kisunla.

J&J: Nipocalimab benefit/risk in MG questionable vs Vyvgart

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology